TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24499206

Group type: EXPERIMENTAL
Intervention: Audio feedback during stair-climbing therapy
Number of subjects: 17
Study: 23281332

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral self-help program
Number of subjects: 82

Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 82
Study: 20838049

Group type: EXPERIMENTAL
Intervention: Temporary percutaneous gastric electrical stimulation (TPGES) with low current settings (5-7 mA) for 7-21 days.
Number of subjects: 27

Group type: COMPARATOR
Intervention: TPGES ON period (12-14 days) compared to OFF period (12-14 days).
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Increased stimulation (8-10 mA) for nonresponders for an additional 14-21 days.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Permanent GES implant after TPGES.
Number of subjects: 27
Study: 18973936

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (1 mg twice daily)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Montelukast (4 mg daily)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study: 16159895

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 22
Study: 12624285

Group type: EXPERIMENTAL
Intervention: L-arginine (30 g over 30 minutes)
Number of subjects: 42
Study: 10831521

Group type: EXPERIMENTAL
Intervention: Gold-coated Inflow stent
Number of subjects: 731

Group type: COMPARATOR
Intervention: Uncoated Inflow stainless steel stent
Number of subjects: 731
Study: 9987642

Group type: COMPARATOR
Intervention: Forearm vascular resistance during semierect exercise
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Blood pressure measurements during erect treadmill exercise
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Integrated, cardiopulmonary, and carotid baroreceptor sensitivity
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Change in forearm vascular resistance on day 28
Number of subjects: 42
Study: 7874862

Group type: EXPERIMENTAL
Intervention: Fasting for 12 hours
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Fasting for 36 hours
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Fasting for 72 hours
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Fasting (duration not specified)
Number of subjects: 19
Study: 3277578

Group type: EXPERIMENTAL
Intervention: Inpatient Family Intervention
Number of subjects: 169

Group type: COMPARATOR
Intervention: Comparison treatment (hospitalization without family intervention)
Number of subjects: 169
Study: 31992358

Group type: EXPERIMENTAL
Intervention: Pelvic floor rehabilitation (PFR) program
Number of subjects: 128

Group type: COMPARATOR
Intervention: Standard treatment (lifestyle advice, pharmacotherapy with bulking agents or antidiarrheal medication)
Number of subjects: 128
Study: 29714527

Group type: EXPERIMENTAL
Intervention: Secured ETT
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Secured LMA
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Secured King
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Secured iGel
Number of subjects: 5

Group type: COMPARATOR
Intervention: Unsecured ETT
Number of subjects: 5

Group type: COMPARATOR
Intervention: Unsecured LMA
Number of subjects: 5

Group type: COMPARATOR
Intervention: Unsecured King
Number of subjects: 5

Group type: COMPARATOR
Intervention: Unsecured iGel
Number of subjects: 5

Group type: COMPARATOR
Intervention: Comparison of secured vs unsecured devices
Number of subjects: 5

Group type: COMPARATOR
Intervention: Secured King vs secured ETT
Number of subjects: 5

Group type: COMPARATOR
Intervention: Secured iGel vs secured ETT
Number of subjects: 5
Study: 27977637

Group type: EXPERIMENTAL
Intervention: Ticagrelor (Tic)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Clopidogrel (Clo)
Number of subjects: 166
Study: 25286912

Group type: EXPERIMENTAL
Intervention: Moral foundation-based frames (harm, fairness, ingroup, authority, purity)
Number of subjects: 0
Study: 22253271

Group type: EXPERIMENTAL
Intervention: Partner presence during epidural catheter insertion (partner-in group)
Number of subjects: 84

Group type: COMPARATOR
Intervention: No partner presence during epidural catheter insertion (partner-out group)
Number of subjects: 84
Study: 20361901

Group type: EXPERIMENTAL
Intervention: Divalproex extended release (ER) at 15 mg/kg/d titrated to a maximum of 30 mg/kg/d
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 18403559

Group type: EXPERIMENTAL
Intervention: Intravenous rtPA
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control (no intravenous rtPA)
Number of subjects: 63
Study: 15999153

Group type: EXPERIMENTAL
Intervention: Tumor-infiltrating B cells in invasive ductal carcinoma (IDC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tumor-infiltrating B cells in medullary breast carcinoma (MBC)
Number of subjects: 0
Study: 11936572

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin with orange juice
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin with calcium-fortified orange juice
Number of subjects: 15

Group type: COMPARATOR
Intervention: Ciprofloxacin with water
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin with calcium-fortified orange juice vs orange juice
Number of subjects: 15
Study: 8829858

Group type: EXPERIMENTAL
Intervention: Ketorolac 0.4 mg.kg‐1 iv, repeated three times at six hour intervals
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diclofenac 1.0 mg.kg‐1 iv after general anaesthesia induction and 1.0 mg.kg‐1 after 12 hr
Number of subjects: 60
Study: 2809260

Group type: EXPERIMENTAL
Intervention: Intraventricular gentamicin therapy
Number of subjects: 21

Group type: COMPARATOR
Intervention: Intravenous antibiotics alone
Number of subjects: 21
Study: 51409

Group type: EXPERIMENTAL
Intervention: Vaccination with live vaccinia virus 14 days before wide local excision
Number of subjects: 48

Group type: COMPARATOR
Intervention: Wide local excision of the primary melanoma
Number of subjects: 48
Study: 31790151

Group type: EXPERIMENTAL
Intervention: Aspirin added to adjuvant chemotherapy
Number of subjects: 880

Group type: COMPARATOR
Intervention: Placebo added to adjuvant chemotherapy
Number of subjects: 880
Study: 28653324

Group type: EXPERIMENTAL
Intervention: Needling
Number of subjects: 60

Group type: COMPARATOR
Intervention: Debridement
Number of subjects: 60
Study: 26280855

Group type: EXPERIMENTAL
Intervention: Short duration tourniquet application
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard duration tourniquet application
Number of subjects: 60
Study: 24016014

Group type: EXPERIMENTAL
Intervention: Alcohol (0.08% target blood alcohol concentration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-alcohol control
Number of subjects: 0
Study: 21654128

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (LDA)
Number of subjects: 28237

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28237

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (LDA) in high-risk group
Number of subjects: 28237

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (LDA) in low-risk group
Number of subjects: 28237
Study: 19134042

Group type: EXPERIMENTAL
Intervention: Epoxy resin-based sealer
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: UDMA resin-based sealer
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sound dentine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Prepared dentine
Number of subjects: 120
Study: 17892526

Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg b.d.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 15577415

Group type: EXPERIMENTAL
Intervention: Genotype/virtual phenotype (vPt)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Real phenotype (rPt)
Number of subjects: 303
Study: 11510871

Group type: EXPERIMENTAL
Intervention: 15% below average power output TT
Number of subjects: 13

Group type: COMPARATOR
Intervention: 15% above average power output TT
Number of subjects: 13

Group type: COMPARATOR
Intervention: Self-selected pace TT (SS)
Number of subjects: 13
Study: 9927886

Group type: EXPERIMENTAL
Intervention: Educational program on hypertension
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no educational program)
Number of subjects: 150
Study: 7923842

Group type: EXPERIMENTAL
Intervention: Antibiotics added to treatment by sinus lavage
Number of subjects: 79

Group type: COMPARATOR
Intervention: Sinus lavage without antibiotics
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Bilateral opaque sinus radiographs
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Branhamella catarrhalis cultured
Number of subjects: 79
Study: 3361421

Group type: EXPERIMENTAL
Intervention: Positive recall of ex-spouse (PS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conflictual recall of ex-spouse (C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Positive recall of a friend (PF)
Number of subjects: 60
Study: 406098

Group type: EXPERIMENTAL
Intervention: Oral isosorbide dinitrate (ISDN) 29 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 31812702

Group type: EXPERIMENTAL
Intervention: Astodrimer 1% Gel
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo Gel
Number of subjects: 255
Study: 31299067

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted darunavir monotherapy for 48 weeks
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Higher VAS-measured adherence
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Detectable HIV-1 DNA RAMs
Number of subjects: 81
Study: 28006055

Group type: EXPERIMENTAL
Intervention: Deficient MMR tumors
Number of subjects: 1395

Group type: EXPERIMENTAL
Intervention: Mutant BRAFV600E tumors
Number of subjects: 1395

Group type: EXPERIMENTAL
Intervention: Mutant KRAS tumors
Number of subjects: 1395

Group type: EXPERIMENTAL
Intervention: Deficient MMR tumors of the proximal colon
Number of subjects: 1395

Group type: EXPERIMENTAL
Intervention: Distal colon tumors with mutant KRAS in codon 12
Number of subjects: 1395

Group type: EXPERIMENTAL
Intervention: Distal colon tumors with mutant KRAS in codon 13
Number of subjects: 1395
Study: 26097039

Group type: EXPERIMENTAL
Intervention: ustekinumab 45 mg
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: ustekinumab 90 mg
Number of subjects: 615

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: ustekinumab 45 mg and 90 mg
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: ustekinumab
Number of subjects: 615
Study: 23907381

Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemia (8, 20 and 40 mU m(-2) min(-1))
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemia
Number of subjects: 20
Study: 22230809

Group type: EXPERIMENTAL
Intervention: colestimide 4g/day (T group, n=23)
Number of subjects: 43

Group type: COMPARATOR
Intervention: continuation of current therapy (C group, n=20)
Number of subjects: 43
Study: 20716842

Group type: EXPERIMENTAL
Intervention: Telmisartan/HCT
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Losartan/HCT
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 20
Study: 17418428

Group type: EXPERIMENTAL
Intervention: Ketamine and atropine intramuscularly (group K, n=50)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ketamine, atropine and midazolam intramuscularly (group KM, n=50)
Number of subjects: 100
Study: 15842550

Group type: EXPERIMENTAL
Intervention: 15 mg morphine sulphate (M)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 15 mg oxycodone hydrochloride (O)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination M10/O5
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination M7.5/O7.5
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination M5/O10
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 12
Study: 12498544

Group type: EXPERIMENTAL
Intervention: Exercise at WBGT of 22.5 degrees C
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Exercise at WBGT of 26.5 degrees C
Number of subjects: 7

Group type: COMPARATOR
Intervention: Exercise conducted during the preceding afternoon
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Repeated exercise bouts on successive days
Number of subjects: 7
Study: 15168720

Group type: EXPERIMENTAL
Intervention: Once-daily didanosine (ddI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Twice-daily stavudine (d4T) plus once-daily ddI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 7808252

Group type: EXPERIMENTAL
Intervention: Overtraining group (OT) - exercised daily for 2 weeks at 100% of 1 RM
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (CON) - exercised 1 day/week at 50% of 1 RM
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Overtraining group (OT)
Number of subjects: 17
Study: 2780876

Group type: EXPERIMENTAL
Intervention: 50 mg of chlorpromazine (CPZ)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 413639

Group type: EXPERIMENTAL
Intervention: Serogroup A meningococcal polysaccharide vaccine
Number of subjects: 176646

Group type: COMPARATOR
Intervention: Tetanus toxoid
Number of subjects: 176646
Study: 31180512

Group type: EXPERIMENTAL
Intervention: Mandibular advancement splint (MAS) + oral EPAP
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Mandibular advancement splint (MAS) + oral/nasal EPAP
Number of subjects: 22

Group type: COMPARATOR
Intervention: Mandibular advancement splint (MAS) alone
Number of subjects: 22
Study: 28029308

Group type: EXPERIMENTAL
Intervention: Early integrated palliative care (PC)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 350
Study: 25468945

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 2072

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 2072

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg and 300 mg
Number of subjects: 2072

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2072
Study: 24118671

Group type: EXPERIMENTAL
Intervention: 75 mg lomitapide on Day 1 followed by 200 mg on Day 3
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg BID
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 400 mg moxifloxacin on Day 3
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 21795553

Group type: EXPERIMENTAL
Intervention: 5 Hz rTMS for 5 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5 days rTMS to motor cortex
Number of subjects: 0
Study: 19459475

Group type: EXPERIMENTAL
Intervention: Grifor vaccine
Number of subjects: 300

Group type: COMPARATOR
Intervention: Vaxigrip vaccine
Number of subjects: 300
Study: 16321485

Group type: EXPERIMENTAL
Intervention: Hop extract (100 microg 8‐PN)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Hop extract (250 microg 8‐PN)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Hop extract (100 microg and 250 microg 8‐PN)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 15042278

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 23
Study: 11122838

Group type: EXPERIMENTAL
Intervention: Rituximab (unconjugated anti-CD20 monoclonal antibody)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cytokines (e.g., interferon-alpha, interleukin-2, interleukin-12)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radioimmunotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vaccine strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antigen-presenting cells (dendritic cells)
Number of subjects: 0
Study: 9062869

Group type: EXPERIMENTAL
Intervention: Melatonin treatment (0.5 mg at bedtime for 7 days)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Melatonin treatment (50 mg daily at bedtime for 37 days)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (at bedtime for 7 days)
Number of subjects: 21
Study: 8366176

Group type: EXPERIMENTAL
Intervention: 300 mg cyclosporine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Aspirin 960 mg three times daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Coadministration of cyclosporine and aspirin
Number of subjects: 24
Study: 3733279

Group type: EXPERIMENTAL
Intervention: Brand A
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Brand B
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Brand C
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous dipyridamole
Number of subjects: 12

Group type: COMPARATOR
Intervention: All brands (A, B, C)
Number of subjects: 12
Study: 28767552

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept
Number of subjects: 79

Group type: COMPARATOR
Intervention: Intravitreal bevacizumab
Number of subjects: 79
Study: 26936601

Group type: EXPERIMENTAL
Intervention: Immune-enhancing dietary supplement for 7 days before and 5 days after surgery
Number of subjects: 128

Group type: COMPARATOR
Intervention: Dietary advice
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Immune-enhancing dietary supplement
Number of subjects: 128
Study: 25898762

Group type: EXPERIMENTAL
Intervention: Foundation products with hygroscopic moisturizing ingredients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Foundation products without hygroscopic moisturizing ingredients
Number of subjects: 0
Study: 22480696

Group type: EXPERIMENTAL
Intervention: Preterm children
Number of subjects: 69

Group type: COMPARATOR
Intervention: Full-term controls
Number of subjects: 69
Study: 20465854

Group type: EXPERIMENTAL
Intervention: Strength Training Group (STG) - high-intensity isometric neck strengthening exercises with an elastic band
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Endurance Training Group (ETG) - lighter dynamic neck muscle training
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control Group (CG) - received a single session of guidance on stretching exercises
Number of subjects: 180
Study: 17905023

Group type: EXPERIMENTAL
Intervention: Lidocaine lollipop
Number of subjects: 50

Group type: COMPARATOR
Intervention: Lidocaine spray
Number of subjects: 50
Study: 15343354

Group type: EXPERIMENTAL
Intervention: Sodium Reduction intervention
Number of subjects: 1157

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 1157
Study: 12221879

Group type: EXPERIMENTAL
Intervention: Clofelin (2.6 +/- 0.15 micrograms/kg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl, 20.0)
Number of subjects: 28
Study: 10574584

Group type: EXPERIMENTAL
Intervention: Alendronate treatment
Number of subjects: 6082

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6082
Study: 7787157

Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg h.s.
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg h.s.
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg b.i.d.
Number of subjects: 121
Study: 2156886

Group type: EXPERIMENTAL
Intervention: Synthetic porcine BNP (2 pmol/kg.min)
Number of subjects: 8
Study: 538766

Group type: EXPERIMENTAL
Intervention: Aspartame in solution (100 mg/kg body weight)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Aspartame in slurry (100 mg/kg body weight)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Aspartame in solution and slurry (100 mg/kg body weight)
Number of subjects: 6
Study: 31524020

Group type: EXPERIMENTAL
Intervention: Graded activity
Number of subjects: 89

Group type: COMPARATOR
Intervention: Other elements of CBT
Number of subjects: 89
Study: 27806969

Group type: EXPERIMENTAL
Intervention: Summer camp for 2 weeks and 4 repetition weekends
Number of subjects: 90

Group type: COMPARATOR
Intervention: Lifestyle school including 4 days family education
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Summer camp
Number of subjects: 90
Study: 25993805

Group type: EXPERIMENTAL
Intervention: Compound DCR (1.8 g · d(‐1))
Number of subjects: 79

Group type: COMPARATOR
Intervention: Diclofenac sodium (75 mg · d(‐1))
Number of subjects: 79
Study: 24261608

Group type: EXPERIMENTAL
Intervention: Micafungin 100 mg intravenously once a day for 14 days
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Micafungin
Number of subjects: 260
Study: 21443356

Group type: EXPERIMENTAL
Intervention: Memory training
Number of subjects: 1401
Study: 19696660

Group type: EXPERIMENTAL
Intervention: 3 g of 75% fucoidan capsules for 12 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: 3 g of guar gum capsules for 12 days
Number of subjects: 20
Study: 16419441

Group type: EXPERIMENTAL
Intervention: High communal-learning context
Number of subjects: 78

Group type: COMPARATOR
Intervention: Low communal-learning context
Number of subjects: 78
Study: 12923013

Group type: EXPERIMENTAL
Intervention: Hand held echocardiographic device
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Continuous wave Doppler measurements
Number of subjects: 98
Study: 10475182

Group type: EXPERIMENTAL
Intervention: Tenecteplase (30-50 mg according to body weight)
Number of subjects: 16949

Group type: COMPARATOR
Intervention: Alteplase (<= 100 mg)
Number of subjects: 16949

Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 16949

Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 16949
Study: 8557121

Group type: EXPERIMENTAL
Intervention: In vitro fertilization and embryo transfer (IVF-ET)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRH-a)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Purified FSH preparations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strategies for OHSS prevention (intravenous albumin, triggering with GnRH-a, withholding menotropin therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cryopreservation of all embryos
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IVF-ET
Number of subjects: 0
Study: 1816845

Group type: EXPERIMENTAL
Intervention: 1% C31G-containing toothpaste
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: C31G-containing toothpaste in different concentrations and combinations with and without fluoride
Number of subjects: 96